A Connecticut federal judge has sided with the US Department of Health and Human Services (HHS) in Boehringer Ingelheim's challenge to Medicare’s drug price negotiation programme, rejecting the ...

With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

The Roundup covers notable class action decisions from federal appellate courts and notable Supreme Court class action cert petitions.

Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

By Maggie Fick and Yamini Kalia (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a ...

Additional funding to provide summer/winter break stipends for undergraduate students has been obtained from the Connecticut Business and Industry Association and corporate sponsors such as Pfizer, ...

The heritage of Boehringer Ingelheim in developing medicines for ... Airway wall thickness, emphysema and air trapping are being assessed using CT. By correlating patient characteristics ...

Click’s CEO David Benshoof Klein said: “We look forward to evaluating CT-155 in a pivotal clinical study, working together with Boehringer Ingelheim to achieve FDA and international regulatory ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

GSK also said it would pay $70 million to settle a related whistleblower lawsuit filed by a Connecticut laboratory ... Sanofi and Boehringer Ingelheim. Lawsuits against the companies began ...